Table 2.
Univariate and Multivariate Analysis for Local Control and Overall Survival
| Variable | Local Progression | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariable Analysis | Univariate Analysis | Multivariable Analysis | |||||
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Female sex (vs male) | 0.62 (0.06–5.98) | .68 | NA | NA | 0.84 (0.47–1.49) | .54 | NA | NA |
| Age at start of RT | 0.99 (0.94–1.05) | .82 | NA | NA | 1.01 (0.98–1.03) | .70 | NA | NA |
| Prior liver-directed therapies, No. | 0.99 (0.63–1.54) | .95 | NA | NA | 0.99 (0.85–1.16) | .93 | 1.16 (1.02–1.31) | .03 |
| Tumor size, cm | 0.85 (0.57–1.28) | .44 | NA | NA | 1.13 (1.00–1.27) | .04 | 1.18 (1.04–1.35) | .01 |
| Portal vein thrombosis | 0.52 (0.00–4.58) | .16 | NA | NA | 1.71 (0.99–2.94) | .05 | NA | NA |
| Tumor histologic findings (vs HCC) | ||||||||
| Intrahepatic cholangiocarcinoma | 6.65 (0.89–49.9) | .07 | 31.9 (2.51–406.0) | 0.008 | 0.31 (0.03–3.08) | .32 | NA | NA |
| Metastases | 1.00 (0.08–12.0) | .99 | 2.68 (0.12–59.2) | 0.53 | 0.77 (0.38–1.55) | .46 | NA | NA |
| Cirrhosis | 0.93 (0.14–6.04) | .94 | NA | NA | 1.97 (1.07–3.62) | .03 | NA | NA |
| Type of liver disease (hepatitis C virus vs other) | 1.26 (0.49–3.24) | .64 | NA | NA | 0.96 (0.56–1.66) | .89 | NA | NA |
| Baseline CTP | NA | NA | NA | NA | 1.42 (1.10–1.84) | .007 | 1.43 (1.13–1.80) | .002 |
| Local progression of tumor | NA | NA | NA | NA | 1.33 (0.38–4.62) | .65 | NA | NA |
| Liver transplant | NA | NA | NA | NA | 0.08 (0.01–1.50) | .09 | NA | NA |
| Total dose, mean (range), Gy | 0.95 (0.85–1.07) | .43 | 0.90 (0.80–1.01) | 0.08 | 0.96 (0.93–0.98) | .001 | 0.96 (0.94–0.99) | .007 |
| BED | 0.98 (0.92–1.04) | .55 | NA | NA | 0.98 (0.97–0.99) | <.001 | NA | NA |
Abbreviations: BED, biologically effective dose; CTP, Child-Turcotte-Pugh; HCC, hepatocellular carcinoma; HR, hazard ratio; NA, not applicable; RT, radiation therapy.